Figure 1.
Prediction of CRS by mEASIX at baseline and Kaplan-Meier curves of OS. (A) ROC curve for prediction of severe CRS by m-EASIX: onset of severe CRS was predicted by baseline m-EASIX (AUC = 0.768; P = .032). 1 − Specificity stands for the probability that a true negative will test positive. (B,C) Kaplan-Meier curves of the OS rate in our study population: MCL disease (P < .001) and infusion of brexucabtagene autoleucel (P < .001) associated with a poor OS in comparison with the other diagnoses and products; (B) red, axicabtagene ciloleucel; blue, tisagenlecleucel; and green, brexucabtagene autoleucel; (C) red, B-ALL; blue, DLBCL, TFL, and PMBCL; and green, MCL. AUC, area under the curve; B-ALL, B-cell acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; PMBCL, primary mediastinal large B-cell lymphoma; TFL, transformed follicular lymphoma.

Prediction of CRS by mEASIX at baseline and Kaplan-Meier curves of OS. (A) ROC curve for prediction of severe CRS by m-EASIX: onset of severe CRS was predicted by baseline m-EASIX (AUC = 0.768; P = .032). 1 − Specificity stands for the probability that a true negative will test positive. (B,C) Kaplan-Meier curves of the OS rate in our study population: MCL disease (P < .001) and infusion of brexucabtagene autoleucel (P < .001) associated with a poor OS in comparison with the other diagnoses and products; (B) red, axicabtagene ciloleucel; blue, tisagenlecleucel; and green, brexucabtagene autoleucel; (C) red, B-ALL; blue, DLBCL, TFL, and PMBCL; and green, MCL. AUC, area under the curve; B-ALL, B-cell acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; PMBCL, primary mediastinal large B-cell lymphoma; TFL, transformed follicular lymphoma.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal